Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer
Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Rowan Miller(Queen Mary University of London), Rachel Nirsimloo(Western General Hospital), Marcia Hall(Hillingdon Hospitals NHS Foundation Trust), Lesley Sage, Andrew R. Clamp, Nicholas Counsell(University College London), Laura Farrelly(University College London), Michael-John Devlin, C. Simon Herrington(Edinburgh Cancer Research), Priya Narayanan(Institute of Cancer Research), Valentinos Kounnis(Churchill Hospital), Laura Hughes(University College London), René L. Roux(Churchill Hospital), Rupali Arora(Royal London Hospital), Charlie Gourley(Edinburgh Cancer Research)
Cited by 32
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
|Annals of Oncology|2020|478
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2021|412
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
|The Lancet Oncology|2021|401
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
|Nature Communications|2016|386